Display options
Share it on

J Nucl Cardiol. 2003 May-Jun;10(3):304-10. doi: 10.1016/s1071-3581(03)00362-3.

Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Hidenobu Terai, Masami Shimizu, Hidekazu Ino, Masato Yamaguchi, Kenshi Hayashi, Kenji Sakata, Masaru Kiyama, Tatsumi Hayashi, Masaru Inoue, Junichi Taki, Hiroshi Mabuchi

Affiliations

  1. Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan. [email protected]

PMID: 12794630 DOI: 10.1016/s1071-3581(03)00362-3

Abstract

BACKGROUND: Malignant ventricular tachyarrhythmia (VT) and sudden death are serious events in hypertrophic cardiomyopathy (HCM). However, the pathophysiology of this condition is not well understood. The objective of this study was to evaluate the relationship between cardiac sympathetic nerve activity and the occurrence of VT in HCM patients. Methods and results We studied iodine 123 metaiodobenzylguanidine scintigraphy and 24-hour ambulatory electrocardiographic monitoring in 44 HCM patients, 15 with VT (group A) and 29 without VT (group B). With planar I-123 metaiodobenzylguanidine imaging, the heart-to-mediastinum ratio for early and delayed acquisition and washout rate were calculated. Polar maps of left ventricular myocardium were divided into 20 segments, and the SD of uptake and washout rate in 20 segments were calculated as indices of regional variation. The global washout rate was significantly higher in group A than in group B (26.8 +/- 6.4% vs 17.4 +/- 5.7%, P <.0001), although other parameters including heterogeneity indices did not differ. The logistic multiple regression analysis also determined that washout rate was the most powerful predictor of VT in patients with HCM.

CONCLUSIONS: The occurrence of malignant VT in HCM may be associated with global cardiac sympathetic nerve activity rather than with the heterogeneity of this activity.

References

  1. J Am Coll Cardiol. 1987 Oct;10(4):761-74 - PubMed
  2. J Nucl Med. 1999 Jun;40(6):917-23 - PubMed
  3. Circulation. 1994 Nov;90(5):2534-9 - PubMed
  4. Br Heart J. 1992 Feb;67(2):155-60 - PubMed
  5. J Nucl Med. 2001 Jul;42(7):1017-24 - PubMed
  6. Am J Cardiol. 1981 Aug;48(2):252-7 - PubMed
  7. Circulation. 1998 Nov 3;98(18):1921-7 - PubMed
  8. J Nucl Med. 1999 Jan;40(1):1-5 - PubMed
  9. Circ Res. 1985 Sep;57(3):432-42 - PubMed
  10. Circulation. 1993 Jul;88(1):172-9 - PubMed
  11. Am Heart J. 2001 Aug;142(2):358-62 - PubMed
  12. Am Heart J. 1990 Jun;119(6):1329-37 - PubMed
  13. Circulation. 1992 Sep;86(3):730-40 - PubMed
  14. Am J Cardiol. 1979 Jun;43(6):1242-4 - PubMed
  15. Nucl Med Commun. 1992 Jul;13(7):513-21 - PubMed
  16. Am J Cardiol. 2001 Aug 1;88(3):275-9 - PubMed
  17. Am J Cardiol. 1987 Nov 15;60(14):1137-42 - PubMed
  18. J Nucl Med. 1998 Oct;39(10 ):1667-71 - PubMed
  19. Lancet. 1997 Jul 12;350(9071):127-33 - PubMed
  20. Circulation. 1994 Feb;89(2):667-83 - PubMed
  21. Circulation. 1987 Apr;75(4):877-87 - PubMed
  22. Circulation. 1992 Jul;86(1):247-54 - PubMed
  23. Am J Cardiol. 1993 Oct 15;72(12):973-6 - PubMed
  24. Circulation. 1995 Oct 1;92(7):1680-92 - PubMed
  25. J Nucl Med. 1981 Apr;22(4):358-64 - PubMed
  26. J Nucl Med. 1997 Jan;38(1):49-52 - PubMed
  27. Circulation. 1982 Jun;65(7):1388-94 - PubMed
  28. Circulation. 1989 Nov;80(5):1489-92 - PubMed
  29. J Nucl Med. 2002 Jan;43(1):15-20 - PubMed
  30. Am Heart J. 1989 Oct;118(4):734-8 - PubMed
  31. J Nucl Med. 1995 Nov;36(11):2138-47 - PubMed

Substances

MeSH terms

Publication Types